BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 27249714)

  • 1. Targeted Therapy in Brain Metastases: Ready for Primetime?
    Venur VA; Ahluwalia MS
    Am Soc Clin Oncol Educ Book; 2016; 35():e123-30. PubMed ID: 27249714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular subtyping of brain metastases and implications for therapy.
    Renfrow JJ; Lesser GJ
    Curr Treat Options Oncol; 2013 Dec; 14(4):514-27. PubMed ID: 23907440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The presence of HER2 exon 20 insertion in patients with central nervous system metastases from non-small lung cancer--a potential application in classification for therapy.
    Nicoś M; Krawczyk P; Mlak R; Sawicki M; Jarosz B; Powrózek T; Milanowski P; Trojanowski T; Milanowski J
    Pneumonol Alergol Pol; 2013; 81(4):294-7. PubMed ID: 23744164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer.
    Quéré G; Descourt R; Robinet G; Autret S; Raguenes O; Fercot B; Alemany P; Uguen A; Férec C; Quintin-Roué I; Le Gac G
    BMC Cancer; 2016 Mar; 16():210. PubMed ID: 26968843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming acquired resistance to kinase inhibition: the cases of EGFR, ALK and BRAF.
    Giroux S
    Bioorg Med Chem Lett; 2013 Jan; 23(2):394-401. PubMed ID: 23245516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy?
    Dempke WC; Edvardsen K; Lu S; Reinmuth N; Reck M; Inoue A
    Anticancer Res; 2015 Nov; 35(11):5797-806. PubMed ID: 26504000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted Therapies for Brain Metastases from Breast Cancer.
    Venur VA; Leone JP
    Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27649142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers for personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic Treatment of Brain Metastases.
    Waqar SN; Morgensztern D; Govindan R
    Hematol Oncol Clin North Am; 2017 Feb; 31(1):157-176. PubMed ID: 27912831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives.
    Minguet J; Smith KH; Bramlage P
    Int J Cancer; 2016 Jun; 138(11):2549-61. PubMed ID: 26537995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anaplastic lymphoma kinase inhibitors in brain metastases from ALK+ non-small cell lung cancer: hitting the target even in the CNS.
    Klempner SJ; Ou SH
    Chin Clin Oncol; 2015 Jun; 4(2):20. PubMed ID: 26112806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects.
    Chuang JC; Neal JW; Niu XM; Wakelee HA
    Lung Cancer; 2015 Oct; 90(1):1-7. PubMed ID: 26275476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [MET receptor inhibition: Hope against resistance to targeted therapies?].
    Hochart A; Leblond P; Le Bourhis X; Meignan S; Tulasne D
    Bull Cancer; 2017 Feb; 104(2):157-166. PubMed ID: 27863726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rare mutations in non-small-cell lung cancer.
    D'Arcangelo M; D'Incecco A; Cappuzzo F
    Future Oncol; 2013 May; 9(5):699-711. PubMed ID: 23647298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
    Tan CS; Cho BC; Soo RA
    Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does lung cancer mutation status and targeted therapy predict for outcomes and local control in the setting of brain metastases treated with radiation?
    Wang TJ; Saad S; Qureshi YH; Jani A; Nanda T; Yaeh AM; Rozenblat T; Sisti MB; Bruce JN; McKhann GM; Lesser J; Halmos B; Stoopler MB; Lassman AB; Cheng SK; Isaacson SR
    Neuro Oncol; 2015 Jul; 17(7):1022-8. PubMed ID: 25910841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic Treatment Options for Brain Metastases from Non-Small-Cell Lung Cancer.
    Bulbul A; Forde PM; Murtuza A; Woodward B; Yang H; Bastian I; Ferguson PK; Lopez-Diaz F; Ettinger DS; Husain H
    Oncology (Williston Park); 2018 Apr; 32(4):156-63. PubMed ID: 29684234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted Therapy for Brain Metastases in EGFR-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer.
    Baik CS; Chamberlain MC; Chow LQ
    J Thorac Oncol; 2015 Sep; 10(9):1268-1278. PubMed ID: 26107553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2 and lung cancer.
    Landi L; Cappuzzo F
    Expert Rev Anticancer Ther; 2013 Oct; 13(10):1219-28. PubMed ID: 24134423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapy and elderly people: A review.
    Daste A; Chakiba C; Domblides C; Gross-Goupil M; Quivy A; Ravaud A; Soubeyran P
    Eur J Cancer; 2016 Dec; 69():199-215. PubMed ID: 27855351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.